3 Promising US Penny Stocks With Market Caps Up To $200M

In This Article:

As the U.S. stock market navigates recent fluctuations, with the Nasdaq snapping a seven-week winning streak despite positive earnings from major tech companies, investors are keenly observing opportunities in various sectors. Penny stocks, often viewed as relics of past market eras, continue to offer intriguing possibilities for those willing to explore smaller or newer companies with growth potential. By focusing on penny stocks that demonstrate strong financial health and stability, investors can uncover potential value in these often-overlooked areas of the market.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.7652

$5.56M

★★★★★★

RLX Technology (NYSE:RLX)

$1.61

$2.05B

★★★★★★

LexinFintech Holdings (NasdaqGS:LX)

$3.20

$526.12M

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$158.96M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$69.71M

★★★★★★

ARC Document Solutions (NYSE:ARC)

$3.37

$145.75M

★★★★★★

PHX Minerals (NYSE:PHX)

$3.42

$128.24M

★★★★★☆

Commercial Vehicle Group (NasdaqGS:CVGI)

$3.01

$97.41M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$1.065

$95.79M

★★★★★☆

Super Group (SGHC) (NYSE:SGHC)

$4.08

$2.05B

★★★★★☆

Click here to see the full list of 754 stocks from our US Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Rapid Micro Biosystems

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Rapid Micro Biosystems, Inc. is a life sciences technology company that offers products for detecting microbial contamination in the production of pharmaceuticals, medical devices, and personal care products across various international markets, with a market cap of $47.21 million.

Operations: Rapid Micro Biosystems, Inc. has not reported any specific revenue segments.

Market Cap: $47.21M

Rapid Micro Biosystems, Inc., with a market cap of US$47.21 million, is currently unprofitable but has shown revenue growth potential. The company reported third-quarter 2024 revenue of US$7.6 million, up from US$6.15 million the previous year, while net losses have narrowed slightly to US$11.32 million from US$13.39 million year-over-year. It remains debt-free with short-term assets significantly exceeding liabilities and has an experienced management team in place. The company reaffirmed its 2024 revenue guidance of at least US$27 million, indicating continued growth prospects despite ongoing profitability challenges in the life sciences sector.